Why Cancer?
作者信息
Haycox Alan
机构信息
University of Liverpool Management School, Liverpool, UK.
出版信息
Pharmacoeconomics. 2016 Jul;34(7):625-7. doi: 10.1007/s40273-016-0413-0.
Abstract
摘要
相似文献
1
Why Cancer?
Pharmacoeconomics. 2016 Jul;34(7):625-7. doi: 10.1007/s40273-016-0413-0.
2
[The cost of cancer, why? why?].
Bull Cancer. 2003 Nov;90(11):937.
3
Transient takotsubo syndrome and its recurrence: Why does it happen, why does it end, and why does it rarely reappear?
Int J Cardiol. 2021 May 1;330:142-144. doi: 10.1016/j.ijcard.2021.02.033. Epub 2021 Feb 15.
4
Why is the topic of cancer and pregnancy so important? Why and how to read this book.
Recent Results Cancer Res. 2008;178:1-2. doi: 10.1007/978-3-540-71274-9_1.
5
Cancer. Why obesity may cause cancer.
Harv Health Lett. 2001 Jun;26(8):6.
6
Re: Cancer Screening in the Pediatric Cancer Patient: A Focus on Genitourinary Malignancies, and Why Does a Urologist Need to Know About This?
Eur Urol. 2020 Mar;77(3):390-391. doi: 10.1016/j.eururo.2019.11.025. Epub 2019 Dec 9.
7
Why is PAK4 overexpressed in cancer?
Int J Biochem Cell Biol. 2021 Sep;138:106041. doi: 10.1016/j.biocel.2021.106041. Epub 2021 Jul 15.
8
Evolved tumor suppression: why are we so good at not getting cancer?
Cancer Res. 2011 Jun 1;71(11):3739-44. doi: 10.1158/0008-5472.CAN-11-0342. Epub 2011 May 24.
9
Why not talk about cancer?
Med Womans J. 1946 Nov;53(11):27.
10
Why cancer "control"?
Public Health Rep (1896). 1950 Sep 22;65(38):1203-8.
引用本文的文献
1
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.
BioDrugs. 2025 Aug 8. doi: 10.1007/s40259-025-00732-2.
2
Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
BMJ Open. 2023 Oct 16;13(10):e066378. doi: 10.1136/bmjopen-2022-066378.
3
Introduction of managed entry agreements in Korea: Problem, policy, and politics.
Front Pharmacol. 2023 Apr 13;14:999220. doi: 10.3389/fphar.2023.999220. eCollection 2023.
4
Editorial: Pharmaceutical policy, impact and health outcomes.
Front Pharmacol. 2023 Feb 14;14:1150055. doi: 10.3389/fphar.2023.1150055. eCollection 2023.
5
Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis.
Front Pharmacol. 2022 Aug 22;13:872196. doi: 10.3389/fphar.2022.872196. eCollection 2022.
6
Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya-Findings and Implications.
Vaccines (Basel). 2022 Jul 26;10(8):1185. doi: 10.3390/vaccines10081185.
7
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.
Front Pharmacol. 2022 Jun 16;13:873556. doi: 10.3389/fphar.2022.873556. eCollection 2022.
8
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Pharmacoeconomics. 2022 Jul;40(7):715-724. doi: 10.1007/s40273-022-01161-7. Epub 2022 Jun 29.
9
Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis.
Front Pharmacol. 2022 Jun 1;13:891008. doi: 10.3389/fphar.2022.891008. eCollection 2022.
10
Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.
Front Pharmacol. 2022 Jan 14;12:794363. doi: 10.3389/fphar.2021.794363. eCollection 2021.
本文引用的文献
1
Cancer Drugs Fund 2.0: A Missed Opportunity?
Pharmacoeconomics. 2016 Jul;34(7):629-33. doi: 10.1007/s40273-016-0403-2.
2
How much should the NHS pay for a QALY?
Pharmacoeconomics. 2013 May;31(5):357-9. doi: 10.1007/s40273-013-0062-5.
3
Should NICE's threshold range for cost per QALY be raised? No.
BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.
4
Should NICE's threshold range for cost per QALY be raised? Yes.
BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.
Zotero 插件